Oseltamivir

Chemical formula: C₁₆H₂₈N₂O₄  Molecular mass: 312.405 g/mol  PubChem compound: 65028

Interactions

Oseltamivir interacts in the following cases:

Agents with a narrow therapeutic margin

Clinically important drug interactions involving competition for renal tubular secretion are unlikely, due to the known safety margin for most of these substances, the elimination characteristics of the active metabolite (glomerular filtration and anionic tubular secretion) and the excretion capacity of these pathways. However, care should be taken when prescribing oseltamivir in subjects when taking co-excreted agents with a narrow therapeutic margin (e.g. chlorpropamide, methotrexate, phenylbutazone).

Immunosuppression

Adults, and adolescents 13 years and over

Treatment

Body WeightRecommended dose for 10 days
>40 kg75 mg twice daily

Treatment should be initiated as soon as possible within the first two days of onset of symptoms of influenza.

Post-exposure prevention

Body WeightRecommended dose for 10 days
>40 kg75 mg once daily

Therapy should begin as soon as possible within two days of exposure to an infected individual.

Prevention during an influenza epidemic in the community

The recommended dose for prevention of influenza during a community outbreak is 75 mg oseltamivir once daily for up to 6 weeks or up to 12 weeks in immunocompromised patients.

Children 1 to 12 years of age

Treatment

The following weight-adjusted dosing regimens are recommended for treatment of infants and children 1 year of age or older.

Body WeightRecommended dose for 10 days*
10 kg to 15 kg30 mg twice daily
>15 kg to 23 kg45 mg twice daily
>23 kg to 40 kg60 mg twice daily
>40 kg75 mg twice daily

* The recommended treatment duration in immunocompromised children (≥1 year old) is 10 days.

Treatment should be initiated as soon as possible within the first two days of onset of symptoms of influenza.

Post-exposure prevention

The recommended post-exposure prevention dose of oseltamivir is:

Body Weight<> Recommended dose for 10 days
10 kg to 15 kg30 mg once daily
>15 kg to 23 kg45 mg once daily
>23 kg to 40 kg60 mg once daily
>40 kg75 mg once daily

Infants 0–12 months of age

Treatment

The recommended treatment dose for infants 0-12 months of age is 3 mg/kg twice daily. This is based upon pharmacokinetic and safety data indicating that this dose in infants 0-12 months provides plasma concentrations of the pro-drug and active metabolite that are anticipated to be clinically efficacious with a safety profile comparable to that seen in older children and adults. The following dosing regimen is recommended for treatment of infants 0-12 months of age:

Body weight*<> Recommended dose for 10 days**
Immunocompromised Patients
3 kg9 mg twice daily
4 kg12 mg twice daily
5 kg15 mg twice daily
6 kg18 mg twice daily
7 kg21 mg twice daily
8 kg24 mg twice daily
9 kg27 mg twice daily
10 kg30 mg twice daily

* This table is not intended to contain all possible weights for this population. For all patients under the age of 1 year, 3 mg/kg should be used to determine dose regardless of the weight of the patient.
Treatment should be initiated as soon as possible within the first two days of onset of symptoms of influenza.
** The recommended duration in immunocompromised infants (0-12 months old) is 10 days. See Special Populations, Immunocompromised Patients for more information.

This dosing recommendation is not intended for premature infants, i.e. those with a post-conceptual age less than 36 weeks. Insufficient data are available for these patients, in whom different dosing may be required due to the immaturity of physiological functions.

Post-exposure prevention

The recommended prophylaxis dose for infants less than 1 year of age during a pandemic influenza outbreak is half of the daily treatment dose. This is based upon clinical data in infants and children 1 year of age or older and adults showing that a prophylaxis dose equivalent to half the daily treatment dose is clinically efficacious for the prevention of influenza. The following age-adjusted dosing prophylaxis regimen is recommended for infants 0-12 months of age:

AgeRecommended dose for 10 days
Immunocompromised Patients
0-12 months3 mg/kg once daily

This dosing recommendation is not intended for premature infants, i.e. those with a post-conceptual age less than 36 weeks. Insufficient data are available for these patients, in whom different dosing may be required due to the immaturity of physiological functions.

Renal impairment

Treatment of influenza

Dose adjustment is recommended for adults and adolescents (13 to 17 years of age) with moderate or severe renal impairment. Recommended doses are detailed in the table below.

Creatinine clearanceRecommended dose for treatment
>60 (ml/min)75 mg twice daily
>30 to 60 (ml/min)30 mg twice daily
>10 to 30 (ml/min)30 mg once daily
≤10 (ml/min)Not recommended (no data available)
Haemodialysis patients30 mg after each haemodialysis session
Peritoneal dialysis patients*30 mg single dose

* Data derived from studies in continuous ambulatory peritoneal dialysis (CAPD) patients; the clearance of oseltamivir carboxylate is expected to be higher when automated peritoneal dialysis (APD) mode is used. Treatment mode can be switched from APD to CAPD if considered necessary by a nephrologist.

Prevention of influenza

Dose adjustment is recommended for adults and adolescents (13 to 17 years of age) with moderate or severe renal impairment as detailed in the table below.

Creatinine clearanceRecommended dose for prevention
>60 (ml/min)75 mg once daily
>30 to 60 (ml/min)30 mg once daily
>10 to 30 (ml/min)30 mg every second day
≤10 (ml/min)Not recommended (no data available)
Haemodialysis patients30 mg after every second haemodialysis session
Peritoneal dialysis patients*30 mg once weekly

* Data derived from studies in continuous ambulatory peritoneal dialysis (CAPD) patients; the clearance of oseltamivir carboxylate is expected to be higher when automated peritoneal dialysis (APD) mode is used. Treatment mode can be switched from APD to CAPD if considered necessary by a nephrologist.

There is insufficient clinical data available in infants and children (12 years of age and younger) with renal impairment to be able to make any dosing recommendation.

Probenecid

No dose adjustment is required when co-administering with probenecid in patients with normal renal function. Co-administration of probenecid, a potent inhibitor of the anionic pathway of renal tubular secretion, results in an approximate 2-fold increase in exposure to the active metabolite of oseltamivir.

Pregnancy

Influenza is associated with adverse pregnancy and foetal outcomes, with a risk of major congenital malformations, including congenital heart defects. A large amount of data on oseltamivir exposure of pregnant women from post-marketing reports and observational studies (more than 1000 exposed outcomes during the first trimester) indicate no malformative nor feto/neonatal toxicity by oseltamivir.

However, in one observational study, while the overall malformation risk was not increased, the results for major congenital heart defects diagnosed within 12 months of birth were not conclusive. In this study, the rate of major congenital heart defects following oseltamivir exposure during the first trimester was 1.76% (7 infants out of 397 pregnancies) compared to 1.01% in unexposed pregnancies from the general population (Odds Ratio 1.75, 95% Confidence Interval 0.51 to 5.98). The clinical significance of this finding is not clear, as the study had limited power. Additionally, this study was too small to reliably assess individual types of major malformations; moreover women exposed to oseltamivir and women unexposed could not be made fully comparable, in particular whether or not they had influenza.

Animal studies do not indicate reproductive toxicity.

The use of oseltamivir may be considered during pregnancy if necessary and after considering the available safety and benefit information, and the pathogenicity of the circulating influenza virus strain.

Nursing mothers

In lactating rats, oseltamivir and the active metabolite are excreted in milk. Very limited information is available on children breast-fed by mothers taking oseltamivir and on excretion of oseltamivir in breast milk. Limited data demonstrated that oseltamivir and the active metabolite were detected in breast milk, however the levels were low, which would result in a subtherapeutic dose to the infant. Considering this information, the pathogenicity of the circulating influenza virus strain and the underlying condition of the breastfeeding woman, administration of oseltamivir may be considered, where there are clear potential benefits to breastfeeding mothers.

Carcinogenesis, mutagenesis and fertility

Fertility

Based on preclinical data, there is no evidence that oseltamivir has an effect on male or female fertility.

Effects on ability to drive and use machines

Oseltamivir has no influence on the ability to drive and use machines.

Adverse reactions


Summary of the safety profile

The overall safety profile of oseltamivir is based on data from 6049 adult/adolescent and 1473 paediatric patients treated with oseltamivir or placebo for influenza, and on data from 3990 adult/adolescent and 253 paediatric patients receiving oseltamivir or placebo/no treatment for the prophylaxis of influenza in clinical trials. In addition, 245 immunocompromised patients (including 7 adolescents and 39 children) received oseltamivir for the treatment of influenza and 475 immunocompromised patients (including 18 children, of these 10 oseltamivir and 8 placebo) received oseltamivir or placebo for the prophylaxis of influenza.

In adults/adolescents, the most commonly reported adverse reactions (ARs) were nausea and vomiting in the treatment studies, and nausea in the prevention studies. The majority of these ARs were reported on a single occasion on either the first or second treatment day and resolved spontaneously within 1-2 days. In children, the most commonly reported adverse reaction was vomiting. In the majority of patients, these ARs did not lead to discontinuation of oseltamivir.

The following serious adverse reactions have been rarely reported since oseltamivir has been marketed: Anaphylactic and anaphylactoid reactions, hepatic disorders (fulminant hepatitis, hepatic function disorder and jaundice), angioneurotic oedema, Stevens-Johnson syndrome and toxic epidermal necrolysis, gastrointestinal bleeding and neuropsychiatric disorders.

Tabulated list of adverse reactions

The ARs listed in the tables below fall into the following categories: Very common (≥1/10), common (≥1/100 to <1/10), un2019common (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), and very rare (<1/10,000). ARs are added to the appropriate category in the tables according to the pooled analysis from clinical studies.

Treatment and prevention of influenza in adults and adolescents:

In adult/adolescent treatment and prevention studies, ARs that occurred the most frequently at the recommended dose (75 mg bid for 5 days for treatment and 75 mg od for up to 6 weeks for prophylaxis) are shown in Table 1.

The safety profile reported in subjects who received the recommended dose of oseltamivir for prophylaxis (75 mg once daily for up to 6 weeks) was qualitatively similar to that seen in the treatment studies, despite a longer duration of dosing in the prophylaxis studies.

Table 1. Adverse reactions in studies investigating oseltamivir for treatment and prevention of influenza in adults and adolescents or through post-marketing surveillance:

System Organ
Class (SOC)
Adverse reactions according to frequency
Very commonCommonUncommonRare
Infections and
infestations
 Bronchitis,
Herpes simplex,
Nasopharyngitis,
Upper respiratory
tract infections,
Sinusitis
  
Blood and
lymphatic
system disorders
   Thrombocytopenia
Immune system
disorders
  Hypersensitivity
reaction
Anaphylactic
reactions,
Anaphylactoid
reactions
Psychiatric
disorders
   Agitation,
Abnormal
behaviour, Anxiety,
Confusion,
Delusions,
Delirium,
Hallucination,
Nightmares,
Self-injury
Nervous system
disorders
HeadacheInsomniaAltered level of
consciousness,
Convulsion
 
Eye disorders   Visual disturbance
Cardiac
disorders/b>
  Cardiac
arrhythmia
 
Respiratory,
thoracic and
mediastinal
disorders
 Cough,
Sore throat,
Rhinorrhea
  
Gastrointestinal
disorders
NauseaVomiting
Abdominal pain
(incl. upper
abdominal pain),
Dyspepsia
 Gastrointestinal
bleedings,
Haemorrhagic
colitis
Hepatobiliary
disorders
  Elevated liver
enzymes
Fulminant hepatitis,
Hepatic failure,
Hepatitis
Skin and
subcutaneous
tissue disorders
  Eczema,
Dermatitis,
Rash,
Urticaria
Angioneurotic
oedema,
Erythema
multiforme,
Stevens-Johnson
syndrome,
Toxic epidermal
necrolysis
General
disorders and
administration
site conditions
 Pain
Dizziness (incl.
vertigo),
Fatigue,
Pyrexia,
Pain in limb
  

Treatment and prevention of influenza in children:

A total of 1473 children (including otherwise healthy children aged 1-12 years old and asthmatic children aged 6-12 years old) participated in clinical studies of oseltamivir given for the treatment of influenza. Of those, 851 children received treatment with oseltamivir suspension. A total of 158 children received the recommended dose of oseltamivir once daily in a post-exposure prophylaxis study in households (n=99), a 6-week paediatric seasonal prophylaxis study (n=49) and a 12-week paediatric seasonal prophylaxis study in immunocompromised subjects (n=10).

Table 2 shows the most frequently reported ARs from paediatric clinical trials.

Table 2. Adverse reactions in studies investigating oseltamivir for treatment and prevention of influenza in children (age/weight-based dosing [30 mg to 75 mg o.d.]):

System Organ
Class (SOC)
Adverse reactions according to frequency
Very commonCommonUncommonRare
Infections and
infestations
 Otitis media  
Nervous system
disorders
 Headache  
Eye disorders Conjunctivitis
(including red
eyes, eye
discharge and eye
pain)
  
Ear and
labyrinth
disorders
 EaracheTympanic
membrane disorder
 
Respiratory,
thoracic and
mediastinal
disorders
Cough,
Nasal congestion
Rhinorrhoea  
Gastrointestinal
disorders
VomitingAbdominal pain
(incl. upper
abdominal pain),
Dyspepsia,
Nausea
  
Skin and
subcutaneous
tissue disorders
  Dermatitis
(including allergic
and atopic
dermatitis)
 

Description of selected adverse reactions

Psychiatric disorders and nervous system disorders

Influenza can be associated with a variety of neurologic and behavioural symptoms which can include events such as hallucinations, delirium, and abnormal behaviour, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease.

In patients with influenza who were receiving oseltamivir, there have been postmarketing reports of convulsions and delirium (including symptoms such as altered level of consciousness, confusion, abnormal behaviour, delusions, hallucinations, agitation, anxiety, nightmares), in a very few cases resulting in self-injury or fatal outcomes. These events were reported primarily among paediatric and adolescent patients and often had an abrupt onset and rapid resolution. The contribution of oseltamivir to those events is unknown. Such neuropsychiatric events have also been reported in patients with influenza who were not taking oseltamivir.

Hepato-biliary disorders

Hepato-biliary system disorders, including hepatitis and elevated liver enzymes in patients with influenza-like illness. Th2019ese cases include fatal fulminant hepatitis/hepatic failure.

Other special populations

Paediatric population (infants less than one year of age)

In two studies to characterise the pharmacokinetics, pharmacodynamics and safety profile of oseltamivir therapy in 135 influenza infected children less than one year of age, the safety profile was similar among age cohorts with vomiting, diarrohea and diaper rash being the most frequently reported adverse events. Insufficient data are available for infants who have a post-conceptual age of less than 36 weeks.

Safety information available on oseltamivir administered for treatment of influenza in infants less than one year of age from prospective and retrospective observational studies (comprising together more than 2,400 infants of that age class), epidemiological databases research and postmarketing reports suggest that the safety profile in infants less than one year of age is similar to the established safety profile of children aged one year and older.

Older people and patients with chronic cardiac and/or respiratory disease

The population included in the influenza treatment studies is comprised of otherwise healthy adults/adolescents and patients "at risk" (patients at higher risk of developing complications associated with influenza, e.g. older people and patients with chronic cardiac or respiratory disease). In general, the safety profile in the patients "at risk" was qualitatively similar to that in otherwise healthy adults/adolescents.

Immunocompromised patients

The treatment of influenza in immunocompromised patients were evaluated in two studies receiving standard dose or high dose regimens (double dose or triple dose) of oseltamivir. The safety profile of oseltamivir observed in these studies was consistent with that observed in previous clinical trials where oseltamivir was administered for treatment of influenza in non-immunocompromised patients across all age groups (otherwise healthy patients or "at risk" patients [i.e., those with respiratory and/or cardiac co-morbidities]). The most frequent adverse reaction reported in immunocompromised children was vomiting (28%).

In a 12-week prophylaxis study in 475 immunocompromised patients, including 18 children 1 to 12 years of age and older, the safety profile in the 238 patients who received oseltamivir was consistent with that previously observed in oseltamivir prophylaxis clinical studies.

Children with pre-existing bronchial asthma

In general, the adverse reaction profile in children with pre-existing bronchial asthma was qualitatively similar to that of otherwise healthy children.

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈